Open AccessAdverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial
Author(s) -
Chang Xu,
Jacob Selhub,
Paul F. Jacques,
Nina P. Paynter,
Jean MacFadyen,
Robert J. Glynn,
Paul M. Ridker,
Daniel H. Solomon
Publication year - 2020
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/keaa650
Subject(s) - medicine , interquartile range , hazard ratio , quartile , adverse effect , methotrexate , dose , gastroenterology , randomized controlled trial , proportional hazards model , confidence interval
Methotrexate is widely used at low dosages (LD-MTX) for non-oncologic indications and is associated with a variety of adverse effects (AEs). We sought to determine whether concentrations of the active metabolite, MTX polyglutamates (MTX-PGs) 1-5, correlate with AEs.